Clinical Guide > Resources and References > ARV Reference Tables

Antiretroviral Reference Tables

January 2011

Chapter Contents

Tables from the DHHS Adult and Adolescent Antiretroviral Guidelines

All Tables
Table 1.Outline of the Guidelines Development Process
Table 2.Rating Scheme for Recommendations
Table 3.Laboratory Monitoring Schedule for Patients Prior to and After Initiation of Antiretroviral Therapy
Table 4.Recommendations for Using Drug-Resistance Assays
Table 5a.Preferred and Alternative Antiretroviral Regimens for Antiretroviral Therapy-Naive Patients
Table 5b.Acceptable Antiretroviral Regimens for Treatment-Naive Patients
Table 6.Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy
Table 7.Antiretroviral Components Not Recommended as Initial Therapy
Table 8.Antiretroviral Regimens or Components That Should Not Be Offered At Any Time
Table 9a.Trough Concentrations of Antiretroviral Drugs for Patients Who Have Drug-Susceptible Virus
Table 9b.Trough Concentrations of Antiretroviral Drugs for Treatment-Experienced Patients with Virologic Failure
Table 10.Identifying, Diagnosing, and Managing Acute HIV-1 Infection
Table 11.Drug Interactions between Antiretroviral Agents and Drugs Used to Treat Opioid Addiction
Table 12.Strategies to Improve Adherence to Antiretroviral Therapy
Table 13.Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects
Table 14.Drugs That Should Not Be Used with PI, NNRTI, or CCR5 Antagonist
Table 15a.Drug Interactions between PIs and Other Drugs
Table 15b.Drug Interactions between NNRTIs and Other Drugs
Table 15c.Drug Interactions between NRTIs and Other Drugs (Including ARV Agents)
Table 15d.Drug Interactions between CCR5 Antagonist and Other Drugs
Table 15e.Drug Interactions between Integrase Inhibitor and Other Drugs
Table 16a.Interactions among PIs
Table 16b.Interactions between NNRTIs, MVC, RAL, and PIs
Appendix B
Table 1.Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Table 2.Characteristics of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 3.Characteristics of Protease Inhibitors (PIs)
Table 4.Characteristics of Integrase Inhibitor
Table 5.Characteristics of Fusion Inhibitor
Table 6.Characteristics of CCR5 Antagonist
Table 7.Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency